• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Response to the Selective RET Inhibitor Selpercatinib (LOXO-292) in a Patient With RET Fusion-positive Atypical Lung Carcinoid.

作者信息

Kander Elizabeth M, Shah Manisha H, Zhou Ye, Goyal Ashima, Palmer Joshua D, Owen Dwight H, Shilo Konstantin, Patel Gopal, Raval Raju R, Gonzalez Javier, Nguyen Michele, Olek Elizabeth, Kherani Jennifer, Rothenberg S Michael, Konda Bhavana

机构信息

Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH.

Department of Radiation Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH.

出版信息

Clin Lung Cancer. 2021 May;22(3):e442-e445. doi: 10.1016/j.cllc.2020.06.011. Epub 2020 Jun 18.

DOI:10.1016/j.cllc.2020.06.011
PMID:32660930
Abstract
摘要

相似文献

1
Response to the Selective RET Inhibitor Selpercatinib (LOXO-292) in a Patient With RET Fusion-positive Atypical Lung Carcinoid.RET融合阳性非典型肺类癌患者对选择性RET抑制剂塞尔帕替尼（LOXO-292）的反应
Clin Lung Cancer. 2021 May;22(3):e442-e445. doi: 10.1016/j.cllc.2020.06.011. Epub 2020 Jun 18.
2
Selective RET kinase inhibition for patients with RET-altered cancers.选择性 RET 激酶抑制剂治疗 RET 改变型癌症患者。
Ann Oncol. 2018 Aug 1;29(8):1869-1876. doi: 10.1093/annonc/mdy137.
3
Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib.通过塞普替尼联合克唑替尼克服 RET 融合阳性肺癌患者对选择性 RET 抑制的 MET 依赖性耐药。
Clin Cancer Res. 2021 Jan 1;27(1):34-42. doi: 10.1158/1078-0432.CCR-20-2278. Epub 2020 Oct 20.
4
Selpercatinib: First Approval.塞尔帕替尼：首次批准。
Drugs. 2020 Jul;80(11):1119-1124. doi: 10.1007/s40265-020-01343-7.
5
Complete Response to Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With Fusion-Positive Breast Cancer.一名融合阳性乳腺癌患者对塞尔帕替尼（LOXO-292）选择性RET抑制的完全缓解。
JCO Precis Oncol. 2021 Jan 11;5. doi: 10.1200/PO.20.00282. eCollection 2021.
6
Efficacy of Selpercatinib in Fusion-Positive Non-Small-Cell Lung Cancer.塞尔帕替尼治疗融合阳性非小细胞肺癌的疗效
N Engl J Med. 2020 Aug 27;383(9):813-824. doi: 10.1056/NEJMoa2005653.
7
RET fusions in non-small-cell lung cancer: an emerging target reshaping the treatment paradigm.非小细胞肺癌中的RET融合：重塑治疗模式的新兴靶点
Future Oncol. 2021 Apr;17(12):1445-1448. doi: 10.2217/fon-2020-1297. Epub 2021 Feb 12.
8
RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.RET 溶剂前沿突变介导选择性 RET 抑制在 RET 驱动的恶性肿瘤中的获得性耐药。
J Thorac Oncol. 2020 Apr;15(4):541-549. doi: 10.1016/j.jtho.2020.01.006. Epub 2020 Jan 24.
9
Precision Targeted Therapy with BLU-667 for -Driven Cancers.BLU-667 精准靶向治疗 - 驱动型癌症。
Cancer Discov. 2018 Jul;8(7):836-849. doi: 10.1158/2159-8290.CD-18-0338. Epub 2018 Apr 15.
10
Novel RET Fusion Predicts Response to Selective RET Inhibition With Selpercatinib in Malignant Pheochromocytoma.新型RET融合预测恶性嗜铬细胞瘤对塞普替尼选择性RET抑制的反应。
JCO Precis Oncol. 2021 Nov;5:1160-1165. doi: 10.1200/PO.21.00127.

引用本文的文献

1
[Case Report: Histological Transformation to Atypical Carcinoid in RET Fusion-positive NSCLC Following Immune Therapy Resistance].[病例报告：免疫治疗耐药后RET融合阳性非小细胞肺癌组织学转化为非典型类癌]
Zhongguo Fei Ai Za Zhi. 2025 May 20;28(5):400-404. doi: 10.3779/j.issn.1009-3419.2025.102.14.
2
Lung Carcinoid Tumors With Potentially Actionable Genomic Alterations and Responses to Targeted Therapies.具有潜在可操作基因组改变及对靶向治疗反应的肺类癌肿瘤
Clin Lung Cancer. 2025 Jul;26(5):354-363.e5. doi: 10.1016/j.cllc.2025.03.009. Epub 2025 Mar 25.
3
Emerging Precision Medicine Approaches for Lung Neuroendocrine Tumors.
肺神经内分泌肿瘤的新兴精准医学方法
Cancers (Basel). 2023 Nov 25;15(23):5575. doi: 10.3390/cancers15235575.
4
-Altered Cancers-A Tumor-Agnostic Review of Biology, Diagnosis and Targeted Therapy Activity.- 改变的癌症——肿瘤非特异性生物学、诊断及靶向治疗活性综述
Cancers (Basel). 2023 Aug 17;15(16):4146. doi: 10.3390/cancers15164146.
5
Response to selpercatinib in a patient with fusion-positive pulmonary large-cell neuroendocrine carcinoma: A case report.1例RET融合阳性肺大细胞神经内分泌癌患者对塞尔帕替尼的反应：病例报告
Front Oncol. 2023 Mar 14;13:1134151. doi: 10.3389/fonc.2023.1134151. eCollection 2023.